Artesunate interactions
Full monograph for ArtesunateCheck it against another medicine
Medicines
68 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Eluxadoline | Major | Metabolism | Coadministration with inhibitors of organic anion transporting polypeptide (OATP) 1B1 may significantly increase the plasma concentrations of eluxadoline… | 8 sources — open the full entry |
| Alpelisib | Moderate | Excretion | Coadministration with alpelisib may theoretically increase the plasma concentrations of drugs that are substrates of organic anion transporter (OAT3)… | 5 sources — open the full entry |
| Amlodipine Besilate + Valsartan | Moderate | Others | Coadministration with inhibitors of the hepatic uptake transporter OATP 1B1 (e.g., rifampin, cyclosporine, paritaprevir) or the hepatic efflux transporter MRP2… | 11 sources — open the full entry |
| Apalutamide | Moderate | Absorption · Metabolism | Coadministration with apalutamide may decrease the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 3A4, 2C9, 2C19, breast… | 5 sources — open the full entry |
| Asciminib | Moderate | Others | Coadministration with asciminib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. In vitro… | 1 sources — open the full entry |
| Axitinib | Moderate | Others | Coadministration with potent inhibitors of uridine diphosphate glucuronosyltransferase (UGT) may increase the peak plasma concentration (Cmax) and systemic… | 4 sources — open the full entry |
| Brigatinib | Moderate | Excretion | Coadministration with brigatinib may increase the plasma concentrations and risk of adverse effects of drugs that are substrates of P-glycoprotein (P-gp)… | 4 sources — open the full entry |
| Cabozantinib | Moderate | Others | Based on in vitro inhibition data, coadministration with cabozantinib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein… | 2 sources — open the full entry |
| Capmatinib Hydrochloride | Moderate | Absorption | Coadministration with capmatinib may increase the plasma concentrations and risk of adverse effects of drugs that are substrates of P-glycoprotein (P-gp)… | 1 sources — open the full entry |
| Carbamazepine | Moderate | Metabolism | Coadministration with potent inducers of uridine diphosphate glucuronosyltransferase (UGT) may decrease the peak plasma concentration (Cmax) and systemic… | 1 sources — open the full entry |
| Ceritinib | Moderate | Excretion | Coadministration with ceritinib may increase the plasma concentrations and the risk of adverse effects of orally administered drugs that are substrates of the… | 2 sources — open the full entry |
| Crizotinib | Moderate | Metabolism | Coadministration with crizotinib may theoretically increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of CYP450… | 5 sources — open the full entry |
| Daclatasvir | Moderate | Excretion | Coadministration with daclatasvir may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed… | 2 sources — open the full entry |
| Daclatasvir + Sofosbuvir | Moderate | Excretion | Coadministration with daclatasvir may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed… | 2 sources — open the full entry |
| Darolutamide | Moderate | Metabolism | Coadministration with darolutamide may increase the plasma concentrations of drugs that are substrates of the breast cancer resistance protein (BCRP)… | 3 sources — open the full entry |
| Diclofenac Diethylamine + Mephenesin + Menthol + Methyl Salicylate + Turpentine Oil | Moderate | Others | Coadministration with potent inhibitors of uridine diphosphate glucuronosyltransferase (UGT) may increase the peak plasma concentration (Cmax) and systemic… | 4 sources — open the full entry |
| Diclofenac Potassium | Moderate | Others | Coadministration with potent inhibitors of uridine diphosphate glucuronosyltransferase (UGT) may increase the peak plasma concentration (Cmax) and systemic… | 4 sources — open the full entry |
| Diclofenac Sodium | Moderate | Others | Coadministration with potent inhibitors of uridine diphosphate glucuronosyltransferase (UGT) may increase the peak plasma concentration (Cmax) and systemic… | 4 sources — open the full entry |
| Diclofenac Sodium + Lidocaine Hydrochloride | Moderate | Others | Coadministration with potent inhibitors of uridine diphosphate glucuronosyltransferase (UGT) may increase the peak plasma concentration (Cmax) and systemic… | 4 sources — open the full entry |
| Diclofenac Sodium + Methyl Salicylate + Linseed Oil + Menthol | Moderate | Others | Coadministration with potent inhibitors of uridine diphosphate glucuronosyltransferase (UGT) may increase the peak plasma concentration (Cmax) and systemic… | 4 sources — open the full entry |
| Diclofenac Sodium + Misoprostol | Moderate | Others | Coadministration with potent inhibitors of uridine diphosphate glucuronosyltransferase (UGT) may increase the peak plasma concentration (Cmax) and systemic… | 4 sources — open the full entry |
| Elacestrant | Moderate | Absorption | Coadministration with elacestrant may increase the plasma concentrations of drugs that are substrates of P-glycoprotein (P-gp) and/or breast cancer resistance… | 1 sources — open the full entry |
| Elagolix Sodium | Moderate | Others | Coadministration with elagolix may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed… | 2 sources — open the full entry |
| Eltrombopag Olamine | Moderate | Metabolism | Coadministration with eltrombopag may increase the plasma concentrations of drugs that are substrates of the organic anion transporting polypeptide (OATP) 1B1… | 7 sources — open the full entry |
| Enasidenib | Moderate | Distribution | Based on in vitro data, coadministration with enasidenib may increase the plasma concentrations of drugs that are substrates of the transporters, organic anion… | 3 sources — open the full entry |
| Enzalutamide | Moderate | Metabolism | Coadministration with enzalutamide may decrease the plasma concentrations of drugs that are substrates of CYP450 3A4, 2C9, 2C19, and/or P-glycoprotein (P-gp)… | 4 sources — open the full entry |
| Erdafitinib | Moderate | Distribution | Coadministration with erdafitinib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) efflux transporter… | 1 sources — open the full entry |
| Flibanserin | Moderate | Others | Coadministration with flibanserin may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) efflux transporter. | 2 sources — open the full entry |
| Gemfibrozil | Moderate | Others | Coadministration with potent inhibitors of uridine diphosphate glucuronosyltransferase (UGT) may increase the peak plasma concentration (Cmax) and systemic… | 4 sources — open the full entry |
| Gilteritinib Fumarate | Moderate | Absorption | Coadministration with gilteritinib may increase the plasma concentrations and the risk of adverse effects of orally administered drugs that are substrates of… | 3 sources — open the full entry |
| Ibrutinib | Moderate | Absorption | Coadministration with ibrutinib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) efflux transporter. In vitro… | 21 sources — open the full entry |
| Imatinib Mesylate | Moderate | Others | Coadministration with potent inhibitors of uridine diphosphate glucuronosyltransferase (UGT) may increase the peak plasma concentration (Cmax) and systemic… | 4 sources — open the full entry |
| Istradefylline | Moderate | Others | Coadministration with istradefylline may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed… | 2 sources — open the full entry |
| Lamivudine + Zidovudine + Nevirapine | Moderate | Antagonism | Coadministration with nevirapine may decrease the peak plasma concentration (Cmax) and systemic exposure (AUC) of dihydroartemisinin (DHA), an active… | 1 sources — open the full entry |
| Lapatinib | Moderate | Metabolism | Coadministration with lapatinib may increase the plasma concentrations of drugs that are substrates of the CYP450 2C8 isoenzyme, CYP450 3A4 isoenzyme, and/or… | 6 sources — open the full entry |
| Lasmiditan Hemisuccinate | Moderate | Distribution | Coadministration with lasmiditan may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) and/or breast cancer… | 1 sources — open the full entry |
| Ledipasvir + Sofosbuvir | Moderate | Absorption · Metabolism | Coadministration with ledipasvir may increase the plasma concentrations of orally administered drugs that are substrates of the P-glycoprotein (P-gp) and/or…2 documented mechanisms | 2 sources — open the full entry |
| Lopinavir + Ritonavir | Moderate | Others | Coadministration with ritonavir may decrease the peak plasma concentration (Cmax) and systemic exposure (AUC) of dihydroartemisinin (DHA), an active metabolite… | 3 sources — open the full entry |
| Lorlatinib | Moderate | Excretion | Coadministration of lorlatinib with drugs that are P-glycoprotein (P-gp) substrates may decrease the plasma concentration and pharmacologic effect of the P-gp… | 4 sources — open the full entry |
| Nebivolol + Valsartan | Moderate | Others | Coadministration with inhibitors of the hepatic uptake transporter OATP 1B1 (e.g., rifampin, cyclosporine, paritaprevir) or the hepatic efflux transporter MRP2… | 11 sources — open the full entry |
| Neratinib Maleate | Moderate | Others | Coadministration with neratinib may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of the breast cancer… | 4 sources — open the full entry |
| Nilotinib | Moderate | Metabolism | Based on in vitro inhibition data, coadministration with nilotinib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein… | 6 sources — open the full entry |
| Nirmatrelvir + Ritonavir | Moderate | Others | Coadministration with ritonavir may decrease the peak plasma concentration (Cmax) and systemic exposure (AUC) of dihydroartemisinin (DHA), an active metabolite… | 3 sources — open the full entry |
| Olaparib | Moderate | Metabolism | Based on in vitro inhibition data, coadministration with olaparib may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 (e.g… | 12 sources — open the full entry |
| Osimertinib | Moderate | Others | Coadministration with osimertinib may increase the exposure of breast cancer resistance protein (BCRP) transporter substrates. In vitro studies have shown that… | 3 sources — open the full entry |
| Oteseconazole | Moderate | Absorption · Metabolism | Coadministration with oteseconazole may increase the plasma concentrations of drugs that are substrates of the breast cancer resistance protein (BCRP), which… | 1 sources — open the full entry |
| Pazopanib Hydrochloride | Moderate | Others | Coadministration with potent inhibitors of uridine diphosphate glucuronosyltransferase (UGT) may increase the peak plasma concentration (Cmax) and systemic… | 4 sources — open the full entry |
| Phenytoin Sodium | Moderate | Metabolism | Coadministration with potent inducers of uridine diphosphate glucuronosyltransferase (UGT) may decrease the peak plasma concentration (Cmax) and systemic… | 1 sources — open the full entry |
| Ponatinib Hydrochloride | Moderate | Others | Based on in vitro inhibition data, coadministration with ponatinib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein… | 2 sources — open the full entry |
| Revefenacin | Moderate | Metabolism | Coadministration of revefenacin with inhibitors of organic anion transporting polypeptide (OATP) 1B1 and/or 1B3 may increase systemic exposure to its active… | 7 sources — open the full entry |
This source documents no food, condition or duplication entries for Artesunate.